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Background: In view of the current economic crisis and the resulting austerity measures being implemented by
governments across Europe, public expenditure for substance abuse treatment has increasingly become a subject
of discussion. An EU cross-country comparison would allow an estimation of the total amount of public resources
spent on substance abuse treatment, compare various substance abuse treatment funding options, and evaluate
the division of expenditures between alcohol and illegal drugs. The purpose of this study is to estimate the public
spending of EU countries for alcohol and illegal drug abuse treatment in hospitals.
Methods: Our study uses a uniform methodology in order to enable valid cross-national comparisons. Our data are
drawn from the Eurostat database, which provides anno 2010 data on government spending for the treatment of
illegal drug and alcohol abuse in 21 EU member states. The cross-country comparison is restricted to hospitals, since
data were unavailable for other types of treatment providers. The systematic registration of in- and outpatient data
is essential to monitoring public expenditures on substance abuse treatment using international databases.
Results: Total public spending for hospital-based treatment of illegal drug and alcohol abuse in the 21 EU member
states studied is estimated to be 7.6 billion euros. Per capita expenditures for treatment of illegal drug abuse vary,
ranging from 0.1 euros in Romania to 13 euros in Sweden. For alcohol abuse, that figure varied from 0.9 euros in
Bulgaria to 24 euros in Austria. These results confirm other studies indicating that public expenditures for alcohol
treatment exceed that for illegal drug treatment.
Conclusions: Multiple factors may influence the number of hospital days for alcohol or illegal substance abuse
treatment, and expenditures fluctuate accordingly. In this respect, we found a strong correlation between gross
domestic product (GDP) per capita and public expenditures per hospital day. The prevalence of problematic (illegal
or legal) drug use in a country did not correlate significantly with the number of hospital days. Other factors must
be included in the analysis of public expenditures for the treatment of substance abuse, such as the drug policy in
a given country and the social norms regarding alcohol consumption.
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Illegal drugs and especially alcohol have a significant
health impact on human life in Europe. The burden of
diseases resulting from alcohol and illegal drugs is enor-
mous; together they account for 11% of disability ad-
justed life years (DALY’sa) lost in Europe [1]. The* Correspondence: Delfine.Lievens@UGent.be
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unless otherwise stated.European Monitoring Centre for Drugs and Drug Addic-
tion (EMCDDA) indicated that at least 1.2 million indi-
viduals received some kind of treatment for illegal drug
use in the EU and its candidate countries [2]. In addition,
Rehm, Shield, Rehm, Gmel & Frick [3] estimated that ap-
proximately 1.1 million people with an alcohol use dis-
order in the EU are in treatmentb. A considerable share
of substance abuse treatment is provided in hospitals. EU
countries reported more than 161,000 hospital discharges
for mental and behavioral disorders due to illegal drugLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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From the sheer number of people in treatment, it is clear
that substance abuse treatment has an economic impact.
Rising health care costs have increased pressure on
providers, insurers, and policymakers to monitor the
costs of all health care services [5]. Moreover, public ex-
penditures for substance abuse treatment are increas-
ingly a subject of discussion in view of the economic
crisis and of austerity. The cuts in government spending
across Europe may affect substance abuse treatment;
therefore, it is crucial that policymakers understand the
economic value of substance abuse treatment services
[6,7]. This economic evaluation of substance abuse treat-
ment is gaining momentum [5], and the EU drugs strat-
egy (2013–2020) supports this evolution by stating that
actions must be evidence-based and cost-effective [8].
This puts a new premium on measuring and valuing the
‘return on investment’ of government expenditures for
drug and alcohol abuse interventions [9]. This type of
evaluation method is clearly linked to public expenditure
studies, because it cannot be completed without the esti-
mation of public spending on substance abuse treat-
ment. Some aspects of drug and alcohol policy can be
studied within a single country; for example, secondary
school classrooms can be randomly assigned to receive
one prevention curriculum or another, with effects on
self-reported substance use assessed at follow-up. How-
ever, many important dimensions of policy operate at
the national level, making cross-national comparisons of
both policies and problem severity important.
Unfortunately, making valid cross-national compari-
sons can be surprisingly difficult because of differences
in definitions, data, and organizational structures across
countries. Creating a foundation for cross-national com-
parisons has been a multi-decade endeavor undertaken by
many researchers, notably those at the European Monitor-
ing Centre for Drugs and Drug Addiction (EMCDDA)
[10]. This study contributes to that effort by estimating
public expenditures on hospital-based treatment in a con-
sistent manner for 21 EU member states.
The current study is unique in that few cross-national
comparisons of substance abuse treatment costs have
been conducted. A previous attempt to calculate the
total European cost of illegal drug treatment services
(published in a EMCDDA selected issue in 2011), suf-
fered from limited data [6]. Rehm, Shield, Rehm, Gmel
& Frick [3] estimated the social cost to the EU countries
for the treatment and prevention of harmful alcohol use
and alcohol dependence to be 6.3 billion euros (2010).
However, they did not report on the cost for specific
types of services such as outpatient treatment and in-
patient treatment. As a result, the cost for hospital treat-
ment is unknown. Neither is it possible to prorate the
estimate of Rehm et al. [3] since the cost per episode oftreatment tends to be higher in inpatient settings [6].
Our study aims to remedy this by estimating hospital-
based treatment expenditures.
The study is conducted within the framework of policy
evaluation and therefore focuses on public spending.
Public expenditures are the direct instrument of public
policy and they dominate in the financing of substance
abuse treatment. Within the EU, health care is mainly fi-
nanced by governmental funding because the public re-
sources in the health care system are supported through
general taxation and/or insurance-based systems [11].
Total public expenditures related to illegal drugs and
alcohol (including but not limited to substance abuse
treatment) have been estimated in social cost studies
and public expenditure studies. Such studies have been
conducted in Australia, the United States, Canada and
some EU countries such as Belgium, Luxembourg, the
Netherlands and Sweden [12-27]. While many of these
studies follow a common set of general principles, they
differ in particulars and so cannot support cross-national
comparisons.
Some cross-country studies of costs or public expendi-
tures in the field of alcohol and/or illegal drugs have
been conducted in Europe, including for treatment spend-
ing [6,28-33]. However, while each of these studies are
valuable, they suffer from one or more methodological
problems. Kopp & Fenoglio [31] and the EMCDDA [6]
were confronted with incomplete or imprecise data pro-
vided by the EU member states. Other studies merely
compiled data from different national studies and so were
confronted with data of varying quality [28-30]. Lievens
et al. [32] even concluded that a truly valid cross-country
comparison may be infeasible because of the conceptual
and methodological differences in the national public ex-
penditure studies.
Nevertheless, having an EU cross-country comparison
of the public expenditures for substance abuse treatment
would be valuable for several reasons [10,32,34]. It
would allow one to estimate the total amount of public
resources spent on substance use treatment. Moreover,
it would allow comparison of substance abuse treatment
funding in different countries. Country profiles pro-
viding information on treatment organization and its
budgetary impact could be compiled and used as a first
step in a full economic evaluation to find the most cost-
effective way of organizing substance abuse treatment
[9]. Finally, an EU cross-country comparison would en-
able examination of the division of expenditures between
alcohol and illegal drugs, allowing for recommendations
on resource allocations [35].
The remainder of this paper is organized as follows:
first, public expenditures (including social security funds)
for illegal drug and alcohol treatment in hospitals are
presented and compared across EU countries. This will
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treatment organization across countries. Second, an esti-
mate of the total EU spending on hospital substance
abuse treatment is given. The public expenditures for
illegal drug treatment are compared to expenditures for
alcohol treatment. Finally, we discuss the factors that
may influence the number of hospital days and the ex-
penditures that come with it.
Methods
Particular care was taken to ensure a uniform method-
ology across the EU member states studied in order
to allow a valid cross-national comparison. Databases
of international organizations were analyzed to identify
health care expenditures for alcohol and illegal drug
treatmentc. The online databases of the following organi-
zations were consulted: Organization for Economic
Co-operation and Development (OECD); the European
Commission; the World Health Organization (WHO);
the United Nations (UN); European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA); European
Medicines Agency (EMA); and European Centre for
Disease Prevention and Control (ECDC). One would ex-
pect that these databases provide data on expenditures
for various types of substance abuse treatment services.
In the United States, both inpatient and outpatient cost
of service groups include costs associated with mental
health diagnosis, labs, and surgery services covered by
Medicaid [7]. However, an analysis of the EU databases
makes clear that Eurostat is the only database that pro-
vides consistent and comparable data for treatment
provided in hospitals. Information for other types of treat-
ment providers, such as nursing and specialized residential
care facilities and providers of ambulatory health care are
not consistently available. In view of this limitation, the
current study focuses on hospital treatment.
The Eurostat database is used to measure public
spending on illegal drug and alcohol treatment in hospitals.
This database provides financial data (public health
budgets for each type of treatment provider) with the
System of Health Accountsd and data on hospital activities
(hospital days by diagnosis).
The financial data are collected by the System of
Health Accounts (published by Eurostat, OECD and
WHO), which systematically describes the financial flows
related to health care [36]. For most EU countries, the
public health budgets for each type of treatment provider
are published on the Eurostat website [37], although there
were no data available for six EU member states (Greece,
Estonia, Ireland, Italy, Malta and the United Kingdom). In
the System of Health Accounts, public health expenditures
are identified as those labeled ‘the general government’,
which includes the central, state and local government
and social insurance funds. Hospital expenditures includethe expenditures for general hospitals, for mental health
and substance abuse hospitals, and for other specialty
hospitalse (e.g. hospitals for infectious diseases, rehabili-
tative and preventive services).
Eurostat also publishes hospital activities by diagnosis
[38] for each country; aggregated data are provided for
total hospital discharges and total hospital days. In the-
ory, these hospital statistics cover the activities for gen-
eral, mental health and specialty hospitals [E. Cayotte,
personal communication, August 19, 2013], although six
countries are not able to report the hospital days for all
hospital types. Consultation of the Eurostat and WHO
country metadata indicates that data are missing for
Belgium, Denmark, France, Luxembourg, the Netherlands
and Spain. Therefore, the results for the latter countries
will be presented separately.
Based on the data in the Eurostat database, govern-
ment spending on illegal drug and alcohol treatment in
hospitals was identified using the following formula:
average cost per hospital day hospital days for
treating illegal drug or alcohol disorders
This method has some limitations. The first limitation
is that the average cost per hospital day is calculated by
dividing the public health expenditure of hospitals by
the total hospital days for treating all causes of diseases.
This methodology assumes that all diagnoses have the
same unit cost of treatment, despite the common-sense
notion that the cost per hospital day varies across diag-
nosis. Furthermore, the hospital expenditures figure used
to calculate the average cost per hospital day includes in-
patient, emergency and outpatient services. The Eurostat
database makes no distinction between types of treatment
service. Consequently, the expenditures for outpatient
and emergency services are attributed to inpatient activ-
ities and this leads to an overestimation of the average
cost per hospital day. The second limitation is that the
formula is based on the number of hospital days, but
‘hospital nights’ might be a more suitable term since hos-
pital days are delineated as days in which a person admit-
ted as an inpatient stays overnight in a hospital [39].
Thus, the measure excludes outpatient treatment and
treatment of patients who were not admitted (e.g. those
treated in the emergency room without admission). Never-
theless, economic cost studies frequently use hospital days
to estimate the hospitals costs for treating substance abuse
[15,16,21,27,40-43]. Hospital days are used as a meas-
ure because it is assumed to capture the prevalence of
recorded substance abuse and they take into account
the time spent for treatment. In the Eurostat database,
hospital days with the primary diagnosis of mental and
behavioral disorders due to psychoactive substance use
or alcohol use (ICD10 codesf F10-F19) are included. In
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resource-intensive of these diagnoses is recorded as the
primary diagnosis. Consequently, the public spending for
substance abuse is underestimated because the patients
with a non-substance-abuse-related primary diagnosis
and a substance abuse disorder as secondary diagnosis
are not taken into account. An overestimation is also
possible for patients with a primary diagnosis of sub-
stance abuse and a secondary diagnosis (e.g. liver disease)
that caused an extended stay in the hospital.
This cross-country comparison is conducted for 21 of
the 27 EU member statesg with data anno 2010. The
public expenditures for illegal drug and alcohol treat-
ment in hospitals are reported per capita, as a share of
gross domestic product (GDP) and total. In order to
explain these results, the individual components of the
formula (public expenditure per hospital day, hospital
days for illegal drug or alcohol treatment, and the pro-
portion of hospital days attributable to drug treatment)
and prevalence rates are presented. Additionally, the
total amount of public spending for the EU for illegal
drug and alcohol treatment in hospitals is estimated.
This estimation is restricted to 21 EU member states.
An extrapolation to the EU-27h is not possible given
the lack of data on health expendituresi for six EU
member states (Greece, Estonia, Ireland, Italy, Malta and
the United Kingdom).
Results
Public spending for illegal drug treatment in hospitals
Numeric results
Public expenditures for hospital treatment are presented
in two tables. Table 1 presents the countries that register
the illegal drug treatment hospitals days and expenditures
for all types of hospitals (general, mental health and spe-
cialty hospitals). The countries in Table 2 only provide
data for general (2 countries) and specialty (4 countries)
hospitals.
Table 1 shows that on average the hospital expenditure
for illegal drug treatment in the EU-15 is 2.8 euros per
capita and 0.01% of GDP. Table 1 also shows important
differences between EU countries. Sweden invests the
most in hospital-based illegal drug treatment (per capita
13 euros and 0.035% of GDP), primarily because its costs
per hospital day appear to be extremely high. Austria
(per capita 8 euros and 0.023% of GDP) and Germany
(per capita 6 euros and 0.021% of GDP) complete the
top three, combining fairly high hospital expenditures
(per capita)j with high rates of hospital-based treatment for
illegal drugs. A number of Northern and Eastern European
countries (Bulgaria, Hungary, Romania, Lithuania and
Latvia) reported hospital expenditures lower than 1 euro
per capita and 0.01% of GDP. The cost per hospital day of
these countries is less than one-third of the average inSweden, Austria, and Germany, and this is combined with
rates of hospital-based treatment per capita that are less
than one-sixth in size.
As discussed above, France and Denmark only provide
data for general hospitals. Belgium, Luxembourg, the
Netherlands and Spain have information for specialty
hospitals and general hospitals, but not for mental health
hospitals. Therefore, the expenditure estimates for the
countries in Table 2 are obviously underestimated. None-
theless, Table 2 shows that on average the hospital ex-
penditure for illegal drug treatment in the EU-4 is 9.6
euros per capita and 0.015% of GDP. Luxembourg has the
highest share of hospital days (2.50%) and of expenditures
(34 euros per capita) attributable to illegal drugs in the
EU. This could be explained by its relatively high public
expenditures for hospital care and prevalence of problem
drug use (6.2 per 1.000 capita) [47].
Interpretation
The hospital expenditures for illegal drug treatment are
calculated on the basis of public health expenditures and
hospital days.
First, the average public expenditure per hospital day
across the 15 EU countries is 423 euros per day. Coun-
tries in Western and Southern Europe (except Germany)
spend more than this average, with Sweden reporting
the highest expenditure (1532 euros). Countries in Eastern
Europe reported much less public funding in hospitals.
The lower expenditures of Eastern European countries are
mainly due to the lower economic power in terms of GDP
[48] and the lower proportion of public financing of health
expenditures [49].
Second, the number of hospital days for illegal drug
treatment per 1,000 capita range from 1 to 17 days.
Austria (15), Germany (16) and the Czech Republic (17)
registered the highest number of hospital days, whereas
Lithuania (1) and Romania (1) registered the least num-
ber of hospital days. When comparing hospitals days for
illegal drug treatment to the total number of hospital
days, Sweden (0.88%), Slovakia (0.75%), Germany (0.72%)
and the Czech Republic (0.79%) have the largest propor-
tion of hospital days for illegal drug treatment. This may
indicate that the latter countries organize drug treatment
mainly inside hospitals and/or that they are confronted
with a high number of problem drug users.
To discover whether differences in the prevalence of
problem drug users can explain the observed (differ-
ences in) hospital days, Figure 1l plots the number of
hospital days used for drug treatment versus the number
of problem illegal drug users (12 months prevalence),
both expressed in per capita terms using data from the
statistical bulletin of the EMCDDA [47].
Pearson’s correlation coefficient was used to analyze
the linear association between hospital days and the
Table 2 Hospital days and expenditures for illegal drug treatment (general and specialty hospitals), for 6 EU
countries, 2010
Country Public expenditure
per hospital day
(euros)
Hospital days
for illegal
drugs per
1,000 capita
Proportion of hospital
days attributable
to illegal drug
treatment (%)
Illegal drug treatment
expenditure by
hospitals
(million euros)
Illegal drug treatment
expenditure by
hospitals, per capita
(euros)
Illegal drug treatment
expenditure by
hospitals, as
percentage of GDP
General hospitals
France 1036 0.4 0.04% 29 0.4 0.001%
Denmark* 2125 0.2 0.02% 2 0.4 0.001%
Mean (SD) 1580 (770) 0.3 (0.2) 0.03% (0.02%) 15 (19) 0.4 (0.06) 0.001% (0.0004%)
General and Specialty hospitals (no mental health or substance abuse hospitals)
Luxembourg† 1079 32 2.50% 17 34 0.044%
Spain† 1131 2 0.27% 97 2.1 0.009%
Belgium* 579 2 0.16% 12 1.1 0.003%
Netherlands 1620 0.5d 0.07% 12 0.7 0.002%
Mean (SD) 1102 (426) 9 (15) 0.75% (1.17%) 35 (42) 9.6 (16.6) 0.015% (0.02%)
*Denmark and Belgium have only data with hospitals days available for 2009.
†Contrary to the other countries, the live-born infants (Z38) of Luxembourg and Spain are not included in the total hospital days, and this could lead to an
overestimation of the hospital expenditures.
Table 1 Hospital days and expenditures for illegal drug treatment (general, mental health and specialty hospitals), for
15 EU countries, 2010
Country* Public expenditure
per hospital day
(euros)
Hospital days
for illegal drug
treatment per
1,000 capita
Proportion of hospital
days attributable
to illegal drug
treatment (%)
Illegal drug treatment
expenditure
by hospitals
(million euros)
Illegal drug treatment
expenditure by
hospitals, per
capita (euros)
Illegal drug treatment
expenditure by
hospitals, as
percentage of GDP
Sweden 1532 9 0.88% 123 13.2 0.035%
Austria† 507 15 0.62% 65 7.8 0.023%
Germany 391 16 0.72% 523 6.4 0.021%
Slovenia 432 7 0.59% 6 3.2 0.018%
Finland† 428 6 0.28% 14 2.5 0.008%
Slovakia 165 11 0.75% 9 1.7 0.014%
Poland 167 9 0.70% 55 1.4 0.015%
Czech
Republic
211 17 0.79% 37 3.5 0.025%
Portugal 1045 0.6‡ 0.11% 6 0.6 0.004%
Hungary 121 5 0.28% 6 0.6 0.006%
Latvia† 140 3 0.24% 0.8 0.4 0.005%
Bulgaria 69 3 0.19% 2 0.2 0.004%
Lithuania 113 1 0.06% 0.4 0.1 0.001%
Romania 81 1 0.07% 2 0.1 0.002%
Cyprus† 936 0.01‡ 0.002% 0.006 0.01 0.00003%
Meank (SD) 423 (429) 7 (6) 0.42% (0.31%) 57 (133) 2.8 (3.7) 0.012% (0.01%)
*The European countries are not classified in regions, because no global classification system is available for illegal drugs (contrary to studies on alcohol, which
distinguish geographical areas by drinking traditions and patterns [44]). Drug-related research e.g., ([45,46]) uses different types of classification according to the
investigated type of drugs. Nevertheless, the conclusions for multiple countries are described by the UN geographical regions: Eastern Europe, Northern Europe,
Southern Europe and Western Europe.
†Contrary to the other countries, the live-born infants (Z38) of Austria, Cyprus, Latvia and Finland are not included in the total hospital days, and this could lead to
an overestimation of the hospital expenditures.
‡The data for Cyprus cover only public sector hospitals. Portugal covers all public inpatient institutions and only two private hospitals. Consequently, the hospital
days for illegal drug treatment are underestimated, and this may affect the proportion of hospital days attributable to illegal drug treatment. Therefore, the
hospital days and public expenditures for illegal drug treatment in Cyprus and Portugal will not be further analyzed.
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Figure 1 Prevalence of problem drug use (2007-2011*) versus hospital days for 8 EU countries. *The prevalence for problem drug users
aged 15–64. Depending on the availability of data, prevalence estimates are presented for the years 2007, 08, 09, 10 or 11. †The EMCDDA did not
provide prevalence rates for Slovenia, Finland, Portugal, Hungary, Lithuania and Romania.
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relation is observed (r = −0.468, p = 0.243). This implies
that the high number of hospital days in Sweden,
Slovakia, Austria and Germany cannot be explained by
these country’s prevalence rates of problem drug use.
However, Figure 1 gives an indication of how drug treat-
ment is organized in the 8 EU member states. On the
one hand, Germany, Austria, Slovakia, Poland and the
Czech Republic have a high number of hospital days in
comparison with the prevalence of problem drug use. In
these countries, problem drug users treated in a hospital
stayed three-to-four days on average. On the other hand,
Latvia and Bulgaria report less than one hospital day per
problem drug user despite their having a high prevalence
of problem drug use. It seems that most problem drug
use treatment in these countries is organized outside
hospitals. An alternative explanation could be that these
countries provide less treatment altogether.
Public spending for alcohol treatment in hospitals
Numeric results
Results for public expenditures for alcohol treatment in
hospitals are also presented in two separate tables
(Table 3 and Table 4) depending on whether data were
available for the different types of hospitals. The coun-
tries are divided into four geographical areas based on
the WHO classification concerning drinking traditions
and patterns [44]. However, it is difficult to draw conclu-
sions on a regional level due to missing data for 12 EU
member states (Belgium, Denmark, Estonia, France,
Greece, Ireland, Italy, Luxembourg, Malta, Netherlands,
Spain and the United Kingdom).
Table 3 shows that on average the hospital expenditure
for alcohol treatment in the EU-15 is 8.5 euros per
capita and 0.046% of GDP. We see important differences
between EU countries. The Central-Western and Westerncountry group have the highest expenditures in terms
of GDP (average of 0.066%) and per capita with 24
euros for Austria and 19 euros for Germany. This con-
trasts with many members of the Central-Eastern coun-
try group that reported an average hospital alcohol
treatment spending of 6 euros per capita (0.052% of GDP).
The Nordic country group reported spending of 14 euros
per capita but the lowest expenditures in terms of GDP
(0.038%).
Table 4 provides an overview of the six countries that
provided data limited to general (and specialty) hospitals.
As was the case for Table 2, the expenditures in hospi-
tals in the countries in Table 4 are underestimated. Des-
pite the lack of data from mental health hospitals, on
average the hospital expenditure for alcohol treat-
ment in the EU-4 is 23 euros per capita and 0.035%
of GDP. Luxembourg has the highest hospital ex-
penditure (82 euros per capita and 0.1% of GDP) for alco-
hol treatment in the EU, and the share of hospital days
(5.94%) attributable to alcohol is high in comparison with
the other EU countries (1.81%). At first sight, this could
not be explained by the prevalence of people with alcohol
dependence (which is relatively low; 3.4%) [3].
Interpretation
In this section we explain hospital expenditures for alco-
hol treatment using the financial investment in public
health and hospital use.
The first conclusion is that the public expenditures
per hospital day vary extensively ranging from 69 euros
in Bulgaria to 1532 euros in Sweden. The average in
Eastern European countries of 166 euros is much lower
than the average of the 15 countries studied (423 euros).
Consequently, countries with a similar proportion of
hospital days attributable to alcohol treatment (e.g. Sweden
and Lithuania) could have a different outcome in terms of
Table 3 Hospital days and expenditures for alcohol treatment (general, mental health and specialty hospitals), for 15 EU
countries, 2010
Country Public expenditure
per hospital day
(euros)
Hospital days
for alcohol
treatment per
1,000 capita
Proportion of hospital
days attributable
to alcohol
treatment (%)
Alcohol treatment
expenditure
by hospitals
(million euros)
Alcohol treatment
expenditure by
hospitals, per
capita (euros)
Alcohol treatment
expenditure by
hospitals, as
percentage of GDP
Central-western and western country group (Belgium, France, Ireland, Luxembourg, Netherlands and UK missing)
Austria* 507 47 1.88% 198 23.7 0.069%
Germany 391 49 2.16% 1578 19.3 0.063%
Mean (SD) Central-western
and western country
group
449 (82) 48 (2) 2.02% (0.2%) 888 (976) 21.5 (3.1) 0.066% (0.004%)
Central-eastern and eastern country group (Estonia missing)
Slovenia 432 34 2.69% 30 14.5 0.084%
Slovakia 165 58 4.11% 51 9.5 0.078%
Poland 167 51 4.15% 325 8.5 0.092%
Hungary 121 31 1.76% 38 3.8 0.039%
Latvia* 140 19 1.68% 6 2.7 0.033%
Czech Republic 211 53 2.54% 118 11.3 0.079%
Lithuania 113 19 1.08% 7 2.2 0.026%
Romania 81 13 0.73% 22 1.0 0.018%
Bulgaria 69 13 0.87% 7 0.9 0.019%
Mean (SD) central-eastern
and eastern country
group
166 (109) 32 (18) 2.18% (1.30%) 67 (103) 6.0 (5.0) 0.052% (0.030%)
Nordic countries (Denmark missing)
Sweden 1532 11 1.10% 155 16.6 0.044%
Finland* 428 25 1.19% 57 10.7 0.032%
Mean (SD) nordic
countries
980 (780) 18 (10) 1.14% (0.06%) 106 (69) 13.6 (4.1) 0.038% (0.009%)
Southern Europe (Greece, Italy, Malta and Spain missing)
Portugal 1045 3† 0.49% 29 2.7 0.017%
Cyprus* 936 0.03† 0.01% 0.1 0.1 0.001%
Mean (SD) southern
Europe
990 (78) 1.3 (1.8) 0.25% (0.35%) 14 (20) 1.4 (1.8) 0.009% (0.011%)
Mean (SD) EU-15 423 (429) 28 (19) 1.76% (1.21%) 175 (399) 8.5 (7.4) 0.046% (0.029%)
*The live-born infants (Z38) of Austria, Cyprus, Latvia and Finland are not included in the total hospital days, and this could lead to an overestimation of the
hospital expenditures.
†The data of Cyprus covers only public sector hospitals. Portugal covers all public inpatient institutions and only two private hospitals. Consequently, the hospital
days for alcohol treatment are underestimated, and this may also affect the proportion of hospital days attributable to alcohol treatment. The results of Southern
Europe will not be analyzed due to this missing data.
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expenditures on illegal drug treatment, the lower expendi-
tures of Eastern European countries could be explained by
the mix of public and private funding of health care [49]
and differences in terms of GDP [48].
The second conclusion is that Slovakia, Poland and
the Czech Republic reported the highest number of hos-
pital days for alcohol treatment, with more than 50 hos-
pital days per 1,000 capita, a rate that translates to
alcohol treatment accounting for more than 4% of hos-
pital days in Slovakia and Poland. The Central-Westernand Western country group reported on average 48 hos-
pital days per capita (2.02% of hospital days for alcohol
treatment). In the Nordic countries, the number of hos-
pital days for alcohol treatment is limited to 1.14%. As is
the case for illicit drugs, the hospital days are investi-
gated by looking at a country’s substance abuse treat-
ment organization and the prevalence rates. Rehm et al.
[3] provide an overview of 12-month prevalence rates
for alcohol dependence per European country. In Figure 2,
these prevalence rates are compared with the hospital days
for alcohol.
Table 4 Hospital days and expenditures for alcohol treatment (general and specialty hospitals), for 6 EU countries, 2010
Country Public expenditure
per hospital day
(euros)
Hospital days for
alcohol treatment
per 1,000 capita
Proportion of hospital
days attributable to
alcohol treatment (%)
Alcohol treatment
expenditure
by hospitals
(million euros)
Alcohol treatment
expenditure by
hospitals, per
capita (euros)
Alcohol treatment
expenditure by
hospitals, as
percentage of GDP
General hospitals
Denmark* 2125 3 0.40% 39 7.1 0.017%
France 1036 5 0.52% 331 5.1 0.017%
Mean (SD) 1580 (770) 4 (1) 0.46% (0.08%) 185 (206) 6.1 (1.4) 0.017% (0.0003%)
General and Specialty hospitals (no mental health or substance abuse hospitals)
Luxembourg† 1079 76 5.94% 41 81.9 0.105%
Belgium* 579 9 0.72% 53 4.9 0.015%
Spain† 1131 3 0.38% 143 3.1 0.014%
Netherlands 1620 1 0.19% 34 2.1 0.006%
Mean (SD) 1102 (426) 22 (36) 1.81% (2.76%) 68 (51) 23 (39.3) 0.035% (0.047%)
*Denmark and Belgium have only data with hospitals days available for 2009.
†The live-born infants (Z38) of Luxembourg and Spain are not included in the total hospital days, and this could lead to an overestimation of the
hospital expenditures.
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correlation (r = 0.003, p = 0.991) was found between hos-
pital days and the prevalence of alcohol dependence.
The majority of European countries (8) have a preva-
lence of alcohol dependence between 4% and 6%. An
exceptional case is Hungary, which has the highest
prevalence rate of alcohol dependence with 10.85%,
although the Hungarian number of hospital days for
alcohol treatment lies below the average of the 13
countries studied (32.5 days). It is likely that Hungary,
and Sweden and Bulgaria as well, organize alcohol treat-
ment mostly outside of hospitals because for an esti-
mated average of three-to-five persons with alcohol
dependence [3] only one hospital day is recorded in these
countries. By contrast, Germany, Slovakia, Poland andGermany
Au
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Comparing public spending in the EU-21 for illegal drug
and alcohol treatment in hospitals
Public spending in the EU-21 for illegal drug and alcohol
treatment in hospitals is presented in Table 5. The public
spending of six EU member states (Belgium, Denmark,
France, Luxembourg, the Netherlands and Spain) with data
limited to general and/or specialized hospitals is extrapo-
lated to all types of hospitals. To do this, we pro-rated total
hospital expenditures of the six EU countries in proportion
to the number of patient days associated with substance
abuse treatment. Tables 1 and 3m provide the proportion
of hospital days attributable to illegal drug and alcoholstria
Slovenia
d
wedena
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ital days for 13 EU countries. *The prevalence of men and women
e presented for varying years.
Table 5 Public expenditures for illegal drug and alcohol
treatment in hospitals for 21 EU countries*, 2010
Public
expenditures
(million euros)
Public
expenditures per
capita (euros)
Public
expenditures
in % of GDP
Illegal drug
treatment
1,703 4.7 0.020%
Alcohol
treatment
5,930 16.5 0.069%
Total 7,633 21.2 0.089%
*Source for population and GDP of EU countries: Eurostat [50,51].
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based on population, is 0.56% for illegal drugs and 2.18%
for alcohol.
Table 5 shows that the total EU-21 spending for illegal
drug and alcohol treatment in hospitals is estimated to
be 7,633 million euros or 21 euros per inhabitant; the share
of GDP is 0.089%. The hospital expenditures for alcohol
treatment are three times higher than the expenditures for
illegal drug treatment, due to the higher number of
hospitalization days for alcohol treatment (Tables 1 and 3
report 28 hospital days for alcohol treatment per 1,000
capita as compared to 7 days for illicit drug treatment).
Discussion
This cross-country comparison provides insight into the
public spending of governments in the EU on substance
abuse treatment in hospitals. A uniform methodology
based on international databases is used to provide con-
solidated data on the public expenditures for drug and
alcohol treatment in hospitals. The total public spending
on hospital-based substance abuse treatment is esti-
mated to be 7.6 billion euros in the 21 EU countries.
Three-quarters (77.7%) of these public expenditures are
used for alcohol treatment, while the remaining quarter
(22.3%) is used for illegal drug treatment. That public
spending for alcohol treatment exceeds spending for il-
legal drug treatment is consistent with previous studies
e.g. [17,26,27]. As expected, the estimate of 5.9 billion
euros in public expenditures for alcohol treatment in
hospitals is lower than the estimate of Rehm et al. [3].
They estimated a European cost, including private ex-
penditures, of 6.3 billion euros for alcohol treatment and
prevention. It is difficult to compare these studies and
draw conclusions given the lack of data for all EU mem-
ber states. This points to the importance of an inter-
national database with complete data for all EU countries.
In the United States, data collection on the nominal costs
of billed services attached to each individual client under,
e.g., Medicaid is standardized across the fifty states. That is
not the case in Europe [7].
This study also showed a large variation in public spend-
ing on substance abuse treatment in hospitals across the15 EU member states that did provide comparable data.
These results are discussed by looking at the explaining
factors, the policy implications and limitations of the
study.
Explaining factors
The public spending on hospitalized substance abuse
treatment can be explained by a variation in three
factors: 1) the hospital cost per day, 2) the organization of
substance abuse treatment and 3) the prevalence of prob-
lem illegal drug use and alcohol dependence. We elaborate
on each in turn.
The hospital cost per day is influenced by the structure
of health care expenditures. The health expenditures in
Central‐East and Eastern Europe are much lower than in
the other EU countries, because these countries have
lower GDP per capita [48]. There is a strong (Pearson)
correlation between GDP per capita and the public ex-
penditures per hospital day (r = 0.638, p = 0.002). Next,
the mix of public and private health financing may help
explain differences in public spending on health care
[see Additional file 1]. Most Eastern European countries
are characterized by a limited share of public financing:
56% in Bulgaria, 64% in Hungary and 68% in Slovakia
(one exception is 83% in the Czech Republic) [52]. The
economic crisis affected the public-private financing mix
for countries such as Bulgaria and Slovakia, since they
reported a substantial increase of the private contribu-
tion and a corresponding decrease in public expenditure
in 2010 [53]. It is very likely that Denmark, Sweden and
the Netherlands reported the highest public expendi-
tures per hospital day partly because their proportion of
public financing is high: the Netherlands 86%, Denmark
85% and Sweden 82%. Moreover, in Eastern Europe it
appears that informal patient payments continue to exist
despite reforms within the health care sector [54,55].
Private health insurance and out-of-pocket expenditures
have a negative impact on the accessibility to health
care, and this is linked to the high share of private finan-
cing [56]. Limited accessibility may lead to an additional
limitation of the number of hospital days.
Moreover, public hospital expenditures are influenced
by the source of financing, i.e. general taxation or
insurance-based systems. Countries with predomin-
antly insurance-based systems (e.g. Belgium, France,
the Netherlands, Germany and Luxembourg) have higher
health care expenditures, because the insurance-based
system is characterized by a lower degree of control over
expenditures [11].
The number of hospital days directly influences public
spending for alcohol and drug treatment. These hospital
days are in turn influenced by the organization of sub-
stance abuse treatment in a country [57]. The Western
European countries Austria and Germany reported a
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alcohol and illegal drug treatment. The Eastern European
countries Poland and Slovakia also reported high hospital
days, especially for alcohol treatment. This high number
of hospital admissions/days suggests that these countries
organize drug treatment mainly inside hospitals, while
countries with a low number of hospital days may have
more of a tradition of establishing specialized treatment
outside hospitals. However, an alternative explanation is
that the latter countries have shorter hospital stays. In
fact, a couple of countries with a low number of alcohol
hospital days reported a shorter average in-patient length
of stay for alcohol treatment (e.g. Romania: 11.3 days,
Lithuania: 8.3 days and Sweden: 4.7 days) than Austria
(17.6 days) and Germany (13.3 days). The same conclusion
can be drawn for illegal drug treatment, except for Bulgaria
which reported longer stays for alcohol (27.6 days) and
illegal drug treatment (18 days) [58].
Furthermore, the profile and the preferences of sub-
stance abusers may also influence the organization of
drug treatment. Substance abusers have a personal
preference for a specific type of treatment service that
is based on indicators such as flexibility, accessibility,
proximity of treatment service, etc. [59,60]. Moreover,
clients may prefer outpatient treatment because it en-
tails fewer out-of-pocket expenses. Outpatient treat-
ment allows female clients to continue caring for their
children [61].
In addition to the hospital cost per day and the
organization of substance abuse treatment, we investi-
gated whether the prevalence of illegal drug and alcohol
problems in a country can explain the number of hos-
pital days and the expenditures that come with it. One
might expect that the more a country is confronted with
substance abusers, the higher the hospital occupation for
these problems will be. In fact, this is the presumption
of economic-cost studies using hospital days to estimate
the hospitals costs for treating substance abuse. How-
ever, we found no positive correlation between these two
variables. For example, Latvia and Bulgaria reported a
high prevalence of problem drug use in combination
with a low number of hospital days. In this respect, the
way a country’s drug treatment is organized influences
the relation between prevalence of substance abuse and
number of hospital days. Furthermore, the prevalence
rates could be affected by cultural factors and social
norms regarding substance use. Rehm et al. [62] argue
that alcohol is highly culturally embedded in Southern-
European countries, therefore people in the region are
more likely to deny alcohol dependence and this may re-
sult in lower admissions to hospitals. This shows that
monitoring (trends in) the prevalence of problem drug
users will not suffice to monitor the (trends) in public
expenditure on substance use treatment.It should be noted that the expenditures on alcohol
and illicit drug treatment cannot be explained solely by
looking at the combination of the prevalence of problem
illegal drug use and alcohol dependence, the hospital
cost per day and the organization of substance abuse
treatment in a country. Other factors such as a country’s
cultural and social norms regarding substance use, its
illicit drug or alcohol policy or the labor costs could play
a role as well [6]. We identified an impact of these fac-
tors for the two outliers of this EU cross-country com-
parison. First, Sweden was the outlier in public spending
for illegal drug treatment. Its public expenditure of 13
euros per capita can be explained by the high cost of
hospitalization and the high proportion of hospital days
attributable to illegal drug treatment (see Table 1).
Sweden’s drug policy may be an additional explanatory
factor since Sweden prioritizes a drug free society and
abstinence-driven treatments [63]. This approach may
also be more expensive than other drug treatment pol-
icies. Cost-benefit analyses need to be consulted to deter-
mine which drug treatment investments bring about
(financial) gains. Second, Luxemburg spends the most in
Europe per capita on hospital expenditure for both alco-
hol and illegal drug treatment. The prevalence of prob-
lem illegal drug use (6.2 per 1.000 capita) [47] and the
high proportion of drug clients entering inpatient centers
(79%) [64] influences the number of hospital days for
illicit drugs. For alcohol, the share of hospital days could
not be explained by the prevalence of people with alcohol
dependence. We speculate that the high expenditures
for Luxembourg could be ascribed to the smaller scale
of drug treatment organization that imposes more
costs on the health care budget. These examples dem-
onstrate that multivariate research is necessary to deter-
mine which factors affect public spending on substance
abuse treatment.
Policy implications
This study measured how much European governments
spend treating illicit drug and alcohol problems in hospi-
tals. Governments play an important role in financing
health care, since governments in the EU-21 finance on
average 73% of the health expenditures (see Additional
file 1). This differs from the United States where less
than 50% of health spending is publicly financed. We
would like to highlight the importance of measuring dir-
ect treatment costs in political and policy decision-
making. The comparability of results across countries
provides information for policymakers and public ad-
ministration [10]. The impact of substance abuse treat-
ment in hospitals on a country’s budget is presented,
and these data can be used to illustrate the budgetary
consequences of different drug policies. The cost infor-
mation in this study also provides a valuable basis for
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ment, not just hospital-based spending. It can also con-
tribute to the evaluation of substance abuse interventions
[65,66], since the public expenditure studies provide an
important component for economic evaluation studies:
the public expenditures serve as the independent variable
and outcomes (e.g., OD deaths) as the dependent variable.
Moreover, these economic evaluation studies can be used
to conduct more complete economic evaluations of sub-
stance abuse treatment in EU countries. For example,
country profiles could be developed compiling informa-
tion on treatment organization and budgetary impact.
Ideally, these efforts lead to an evidence-based policy
where financial resources are assigned to cost-effective
substance abuse treatment [67]. However, it remains to
be seen if governments will be willing and able to make
these investments in exchange for benefits in the long-
term (i.e. cost savings and reduced human suffering).
For example, Rehm et al. [3] estimated that less than
10% of people with alcohol dependence in the EU re-
ceive treatmentn. A 10% increase in health care coverage
for hospital-based alcohol treatment in Europe would bring
about an estimated 593-million-euro increase in hospitals’
public expenditure.
Study limitations and recommendations
This study uses data from the Eurostat database to
measure how much European governments spend on
treating illegal drug and alcohol problems in hospitals.
International databases facilitate cross-country compari-
sons that could highlight the impact of substance abuse
on public health budgets [68]. Our cross-country com-
parison is restricted to hospitals since data were unavail-
able for other types of treatment providers. It is not
clear which proportion of the drug and alcohol clients
receive hospital treatment. The Treatment Demand Indi-
cator (TDIo) used in the EU, cannot determine the pro-
portion of substance use clients treated in hospitals
since it only distinguishes between the proportion of il-
legal drug clients in inpatientp and outpatient centers.
The TDI shows that the proportion of reported clients
entering inpatient centers for drug-related problems var-
ies to a large extent by country (from 2% in France to
79% in Luxembourg) [64]q. Notwithstanding the limita-
tions of the current analysis, the impact of hospital ex-
penditures for drug and alcohol treatment on the public
budget should not be underestimated. Multiple studies
e.g. [6,69,70] show that the unit cost for hospital treat-
ment is much higher than for outpatient treatment ser-
vices. For example, inpatient detoxification in England is
provided at a cost of 200 euros per patient per day and
outpatient detoxification is provided at a cost of 8 euros
per patient per day [71]. Moreover, Andlin-Sobocki,
Jönsson, Wittchen and Olesen [72] indicate that thecost for hospital care due to brain disorders in Europe
(including alcohol and illicit drug use disorders) domi-
nates total treatment cost. Public expenditure studies in-
dicate that a large share of the public expenditures for
substance abuse treatment is attributable to care in hos-
pitals. For example, in Belgium the share of hospital
treatment for alcohol and illegal drug use amounts to as
much as 90.66% of the total public spending for sub-
stance abuse treatment [21]. On the other hand, a Swedish
study, with a research scope limited to illegal drugs, found
a much lower share of hospital treatment. Ramstedt [14]
reported that hospital expenditures made up only 16% of
the total illegal drug abuse health spending. In other words,
insight into the expenditures on substance abuse treatment
via hospital expenditures is complex, since it varies with
the investigated substance and with several other factors
discussed above.
The analysis of international data for cross-country
comparison purposes illustrated that, despite the great
potential of these data (bases), much information is still
lacking today. Ideally, these databases should provide
hospital charges categorized according to diagnosis-related
groups, as is the case with the Medicaid database in the
United States [7]. However, the Eurostat database is limited
to public health care expenditures by provider (e.g. ambu-
latory health care, nursing and residential care facilities). In
order to estimate the drug- and alcohol-related percentages
of these budgets, the health care activities by diagnosis are
required for outpatient and inpatient treatment services
(apart from hospital-based treatments). Further research
is necessary to develop variables in international data-
bases that provide data for outpatient treatment ses-
sions for substance abuse, inpatient days for substance
abuse, consultations for substitution treatment, drug
treatment counseling in prisons, etc. This data would
allow researchers to compare public expenditures for
different types of treatment regimes. Additionally these
data could be used for more in-depth economic evalua-
tions, i.e. whether specific treatment modalities are more
cost-effective than others [73,74].
In our study in particular, we were confronted with
the significant limitations of the Eurostat database. In
the Eurostat database, hospital days are limited to pri-
mary diagnosis and health expenditures are not subdi-
vided by inpatient, emergency or outpatient service.
Next, the Eurostat data are sometimes incomplete be-
cause countries are not always able to provide data for
all types of hospitals (general, mental health and spe-
cialty hospitals). A number of EU countries (Belgium,
Denmark, France, Luxembourg, the Netherlands and
Spain) could not report data for mental health hospitals.
Furthermore, the external causes of morbidity (the ICD-
10 codes V00-Y84), such as accidents, intentional self-
harm and assault [75] are not included in the total hospital
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attributable to drugs/alcohol. This in turn leads to an over-
estimation of hospital expenditures for alcohol and illicit
drug treatment in hospitals.
Finally, Eurostat collects health care data via various
public and private information sources in EU countries.
These data reflect the country-specific way of organ-
izing and reporting health care, and this may diminish
comparability across countries [76]. In this respect, the
health expenditures collected by the System of Health
Accounts (SHA) differs from the general government ex-
penditures by COFOG (Classification of the Functions of
Government) functionr. The SHA/COFOG differences
highlight the uncertainty of estimates due to differences
in information sources.
With these limitations in mind, we recommend expand-
ing the Eurostat data collection of hospital discharges
with secondary diagnoses. Furthermore, the data cover-
age of the Eurostat database should be improved to ob-
tain more reliable results for the EU member states
since the consistency of reporting is indispensable for
international benchmarking of budget expenditures across
countries [77].
Conclusion
This study highlighted the need for cross-country com-
parison of the public expenditures for substance abuse
treatment. Despite limitations, this study presents the
public spending for illegal drug and alcohol treatment in
hospitals of 21 EU member states. The study corrobo-
rates other studies that found that public expenditures
for alcohol treatment exceed public expenditures for il-
legal drug treatment. Multiple factors may influence the
number of hospital days and the expenditures that come
with it. In this respect, we found a strong correlation
between GDP per capita and the public expenditures
per hospital day. Other factors should be included in
the future analysis of public expenditures for substance
abuse treatment, such as the drug policy in a given country
(in this study, we especially discussed the case of Sweden)
and the social norms regarding alcohol consumption
(in this study, we especially discussed various Eastern
European countries).
Endnotes
aDALY is a metric to determine the burden of disease.
Therefore, it takes into account the years of potential life
lost (YLL) due to premature mortality and the years of
productive life lost (YLD) due to disability.
bThe number of people with an alcohol use disorder in
treatment is estimated by taking into account the preva-
lence of 11.9 million people with alcohol dependence
and the treatment coverage (in- and outpatient) with a
minimum of 8.7% and maximum of 10.2% [3].cThe analysis of international databases was part of a lar-
ger study on public expenditure on drug treatment that
the authors conducted for the EMCDDA in 2013 [78].
dEurostat also reports “general government expend-
iture by function (COFOG)”. However the COFOG data-
base can only provide data for 19 EU member states
(instead of 21 EU member states with the SHA database),
since there are no data for Belgium, Spain, Romania and
Slovakia. Furthermore, this database does not make a dis-
tinction between expenditures for general hospitals, mental
health and substance abuse hospitals and specialty hospi-
tals (other than mental health and substance abuse hospi-
tals). Consequently, it would not be possible to estimate
hospital expenditures for general and specialty hospitals in
Denmark, France, Luxembourg and Netherlands.
eThe specialty hospitals consists of acute care hospi-
tals; emergency centers; orthopedic hospitals or specialty
sanatoriums primarily engaged in providing medical
post-acute care, rehabilitative and preventive services;
traditional medicine hospitals; and special hospitals for
infectious disease (tuberculosis hospitals, hospitals for
tropical diseases).
fThe International Classification of Diseases (ICD) is
the international coding system of diseases and other
health problems. This standard diagnostic tool is used for
epidemiology, health management and clinical purposes.
gThe European Union reached its current size of 28
member countries with the accession of Croatia on 1
July 2013. Since the analysis is based on 2010 data, Croatia
is not included in this study.
hThe authors also tested an extrapolation by regres-
sion. However, the regression with hospitals days for
substance abuse treatment regressed on GDP per capita
and prevalence of problem substance use was not signifi-
cant (P > 0.05).
iThe health expenditures are indispensable to esti-
mate the cost per hospitalization day. An extrapola-
tion of the health expenditures by population would
neglect the strong correlation between GDP and hos-
pital expenditures.
jSweden (1507 euros), Austria (1259 euros), Finland
(904 euros) and Germany (893 euros) have the highest
hospital expenditures per capita.
kAll means in Tables 1, 2, 3 and 4 are calculated with
the simple average method.
lFigures 1 and 2 give an impression of the relationship
between prevalence and hospital days for substance
abuse. This comparison should be interpreted with cau-
tion, since hospital days are limited to primary diagnosis
of mental and behavioral disorders due to psychoactive
substance use or alcohol use.
mThe data of 15 EU member states are used for ex-
trapolation, because these countries provided data to es-
timate the public expenditures for all hospital types.
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http://www.substanceabusepolicy.com/content/9/1/26nWittchen et al. [79] state that only 25% of persons
with mental disorders receive professional mental health
treatment.
oThe TDI is a monitoring tool developed by the
EMCDDA to gain insight into the characteristics, risk
behaviors and drug use patterns of people with illegal
drug problems. To this end, data are collected on the
number and profile of clients entering drug treatment
during each calendar year. This tool is being used by 30
countries (28 EU member states, plus Norway and
Turkey) who send their national data to the EMCDDA.
pThe inpatient centers include therapeutic communi-
ties, private clinics, units in a hospital and centers that
offer residential facilities.
qThis proportion should be interpreted with caution
since the data coverage of TDI ranges from 14% to 100%
of existing inpatient units in the registering countries.
rThe COFOG is restricted to government administra-
tive sources and focuses on the classification of trans-
actions in government-funded health care [80]. The
COFOG hospital services expenditures (code GF0703)
of 13 EU member states are compared to the SHA
hospital expenditures (code HP1). The COFOG expendi-
tures deviate from the expenditures reported on by the
SHA: a difference of less than 10% in health expenditures
is retrieved for 6 EU member states (Bulgaria, Czech
Republic, Germany, Cyprus, Lithuania and Slovenia) and
more than 10% for 7 EU member states (Latvia, Austria,
Poland, Finland, Hungary, Portugal and Sweden). For
Portugal, the hospital expenditure measured by COFOG
(749 million euros) is only 12.8% of the expenditure col-
lected by SHA (5.843 million euros).
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